Remove 2005 Remove International Remove Licensing
article thumbnail

Landiolol

New Drug Approvals

Baker JG (February 2005). “Beneficial effect of early infusion of landiolol, a very short-acting beta-1 adrenergic receptor blocker, on reperfusion status in acute myocardial infarction” International Journal of Cardiology. 2016 Apr 25;80(5):1106-7 ^ “Rapibloc Summary of Product Characteristics” (PDF).

FDA 62
article thumbnail

Burning Rock Announces an Exclusive in-Licensing of a Risk Stratification Test for Early Stage Lung-Cancer Patients from Oncocyte in China

The Pharma Data

15, 2020 (GLOBE NEWSWIRE) — Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) today announced that it entered into an exclusive licensing agreement with Oncocyte Corporation (NYSE American: OCX) to bring DetermaRx , a risk stratification test for early stage lung cancer patients, to China. 1 Kratz et al.,

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

How nucleolar stress accelerates aging in mice

Drug Target Review

In 2005, he joined CNIO to lead the Genomic Instability Group where he has been ever since. These compounds were later licensed to the pharmaceutical industry for clinical development. Oscar Fernandez-Capetillo did his PhD in the University of The Basque Country working with mouse models of autoimmunity with Dr Ana Zubiaga.

RNA 65
article thumbnail

Novartis presents new findings at ERS reinforcing the efficacy of.

The Pharma Data

Novartis will present 12 abstracts at the European Respiratory Society (ERS) International Congress 2021 for Enerzair ® Breezhaler ® (IND/GLY/MF*) and Atectura ® Breezhaler ® (IND/MF**) — for patients whose asthma is uncontrolled with LABA/ICS^ and ICS, respectively 1,2. g) and medium-dose (150/50/80?g) g) formulations.

article thumbnail

Yesse Technologies secures another grant from The Michael J. Fox Foundation to sniff out Parkinson’s disease

The Pharma Data

Yesse Technologies’ core technology, the ORion21 genetic platform, is the product of over 30 years of fundamental research on the molecular biology of the sense of smell and is exclusively licensed from The City University of New York. The Center is recognized from 2005 onwards as a center of excellence for Parkinson’s disease.

Disease 40
article thumbnail

Tezepelumab NAVIGATOR Phase 3 Trial Met Primary Endpoint Of A Statistically Significant And Clinically Meaningful Reduction In Exacerbations In A Broad Population Of Patients With Severe Asthma

The Pharma Data

Amgen develops product candidates internally and through licensing collaborations, partnerships and joint ventures. J Intern Med 2012;272:121–32. 2005; 172; 149–60. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Last accessed: September 2020 ]. 6 Kupczyk M, Wenzel S.

Trials 52
article thumbnail

Update On SOURCE Phase 3 Trial For Tezepelumab In Patients With Severe, Oral Corticosteroid-Dependent Asthma

The Pharma Data

Amgen develops product candidates internally and through licensing collaborations, partnerships and joint ventures. 2005; 172: 149-160. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. 2019;12(5):539-549. Wenzel S. Severe asthma in adults. Eur Respir J.

Trials 40